Advertisement

Clinical Drug Investigation

, Volume 31, Issue 2, pp 101–111 | Cite as

Assessment of the Potential for Displacement Interactions with Sugammadex

A Pharmacokinetic-Pharmacodynamic Modelling Approach
  • Alex ZwiersEmail author
  • Michiel van den Heuve
  • Jean Smeets
  • Samantha Rutherford
Oriinal Research Article

Abstract

Background: Sugammadex is a γ-cyclodextrin that binds with high affinity to the neuromuscular blocking agents (NMBAs) rocuronium (bromide) and vecuronium (bromide) by encapsulation. Cyclodextrins are known to form inclusion complexes with other compounds.

Objectives: We utilized a previously developed pharmacokinetic-pharmaco-dynamic model to identify potential clinically relevant displacement interactions with sugammadex. The potential for sugammadex to capture other drug molecules, thereby reducing their efficacy, is not discussed here.

Methods: Isothermal titration calorimetry (ITC) was used to determine the binding affinity (estimated by association rate constant [kass]) between sugammadex and 300 commonly prescribed drugs. The screening included drugs commonly used in or shortly after anaesthesia, commonly prescribed drugs such as antidepressants and cardiovascular drugs, drugs (both steroidal and nonsteroidal) acting on steroidal receptors (such as the corticosteroids hydrocortisone, prednisolone and dexamethasone), and the selective estrogen receptor modulator toremifene. The model took into account the population pharmacokinetic-pharmacodynamic relationships of sugammadex, rocuronium and vecuronium, the binding affinities of the NMBAs and other compounds as determined by ITC, and the relationship between the free concentration of NMBA with sugammadex in the presence of a third complexed compound. Using the model, the critical concentrations of a con-comitantly administered compound required to result in a train-of-four (TOF) ratio of <0.9, indicating reoccurrence of neuromuscular blockade, for each plasma concentration of sugammadex and NMBA were calculated. For compounds with a kass value of ≥2.5 ×104 mol/L likely to be administered during sugammadex reversal, the combinations of kass and maximum plasma drug concentration (Cmax) were entered into a graph, consisting of a critical line established using a conservative approach, and those compounds above this critical line potentially resulting in a TOF ratio <0.9 were subsequently identified. Clinical validation was performed in a post hoc analysis of data from ten sugammadex studies, in which the impact of various drugs administered perioperatively on neuromuscular recovery was assessed for up to 1 hour after sugammadex administration.

Results: ITC analysis demonstrated that the binding affinity of rocuronium and vecuronium for sugammadex was very high, with kass values of 1.79 × 107 mol/L and 5.72 × 106 mol/L, respectively. Only three compounds (flucloxacillin, fusidic acid and toremifene) were found to have critical combinations of kass and Cmax, and thus the potential for displacement. Sugammadex was administered to 600 patients for reversal of rocuronium- or vecuronium-induced blockade in the ten analysed studies, in which 21 co-administered drugs were selected for analysis. No reoccurrence of blockade occurred in any patient.

Conclusion: Of 300 drugs screened, only three (flucloxacillin, fusidic acid and toremifene) were found to have potential for a displacement interaction with sugammadex, which might potentially be noticed as a delay in recovery of the TOF ratio to 0.9. A clinical study found no evidence of a clinically relevant displacement interaction of flucloxacillin with sugammadex; these findings confirm the highly conservative nature of the modelling and simulation assumptions in the present study.

Keywords

Vecuronium Rocuronium Isothermal Titration Calorimetry Critical Line Toremifene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported by MSD, Oss, the Netherlands. Alex Zwiers and Michiel van den Heuvel are employees of MSD, Oss, the Netherlands. Samantha Rutherford is an employee of Schering-Plough Research Institute, a division of MSD. Jean Smeets is a former employee of MSD, Oss, the Netherlands, and is currently employed by LAP&P Consultants BV, Leiden, the Netherlands.

The authors thank Ton Bom, MD for collecting and assimilating all of the study data into a database and Jan Huisman for performing SAS programming. Medical writing support was provided by Melanie More at Prime Medica Ltd (Knutsford, Cheshire, UK) during the preparation of this manuscript. Responsibility for the opinions, conclusions and interpretation of the data lies with the authors.

References

  1. 1.
    Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002 Jan 18; 41(2): 266–70PubMedCrossRefGoogle Scholar
  2. 2.
    Bom A, Epemolu O, Hope F, et al. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007 Jun; 7(3): 298–302PubMedCrossRefGoogle Scholar
  3. 3.
    Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003 Sept; 99(3): 632–7PubMedCrossRefGoogle Scholar
  4. 4.
    Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005 Oct; 103(4): 695–703PubMedCrossRefGoogle Scholar
  5. 5.
    Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006 Aug; 97(2): 123–6PubMedCrossRefGoogle Scholar
  6. 6.
    Ploeger BA, Smeets J, Strougo A, et al. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009 Jan; 110(1): 95–105PubMedCrossRefGoogle Scholar
  7. 7.
    Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006 Jan; 96(1): 36–43PubMedCrossRefGoogle Scholar
  8. 8.
    Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006 Apr; 104(4): 667–74PubMedCrossRefGoogle Scholar
  9. 9.
    de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007 Aug; 107(2): 239–44PubMedCrossRefGoogle Scholar
  10. 10.
    Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007 Mar; 104(3): 555–62PubMedCrossRefGoogle Scholar
  11. 11.
    Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007 May; 106(5): 935–43PubMedCrossRefGoogle Scholar
  12. 12.
    Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007 Feb; 106(2): 283–8PubMedCrossRefGoogle Scholar
  13. 13.
    Vanacker BF, Vermeyen KM, Struys MM, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007 Mar; 104(3): 563–8PubMedCrossRefGoogle Scholar
  14. 14.
    Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008 Aug; 109(2): 188–97PubMedCrossRefGoogle Scholar
  15. 15.
    Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008 Oct; 101(4): 492–7PubMedCrossRefGoogle Scholar
  16. 16.
    Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009 Feb; 110(2): 284–94PubMedGoogle Scholar
  17. 17.
    de Kam P-J, Cavens L, van den Heuvel M, et al. Flucloxacillin and diclofenac do not cause reoccurrence of blockade after reversal with sugammadex [abstract]. Anesthesiology 2009; A429Google Scholar
  18. 18.
    Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily in an unchanged form via renal excretion [abstract]. Clin Pharmacol Ther 2009 Feb; 85Suppl 1: S83–4Google Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Alex Zwiers
    • 1
    Email author
  • Michiel van den Heuve
    • 1
  • Jean Smeets
    • 1
  • Samantha Rutherford
    • 2
  1. 1.MSDOssthe Netherlands
  2. 2.a Division of MSDSchering-Plough Research InstituteNewhouseUK

Personalised recommendations